VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, today announces April operational results. DMG April 2026 Preliminary Operational ResultsBitcoin mined: 21 BTC (vs 23 BTC in March 2026) Hashrate: 1.54 EH/s (vs 1.63 EH/s in March 2026) Bitcoin balance: 389 BTC (vs 398 BTC in March 2026)At the end of March, DMG held 389 bitcoin, as the Company liquidated bitcoin to fund operations and capital expenses. Energy Update Although bitcoin pricing is showing some relief recently, DMG’s ability to access wholesale power markets for its Christina Lake operations has allowed it to benefit from the low price of Mid-Columbian Basin power,...

VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) (“Equinox Gold” or the “Company”) is pleased to announce detailed voting results from the Company’s Annual Meeting of Shareholders held on May 7, 2026. A total of 530,033,771 common shares were represented at the meeting, being 66.9% of the Company’s outstanding common shares. Each of the director nominees listed in the Company’s Management Information Circular dated March 23, 2026, which is available on the Company’s website at www.equinoxgold.com, was elected as a director of the Company. Each of the other matters voted on at the meeting, as described in detail below and in the Management Information Circular, was approved. Election of DirectorsDirector Nominee Votes For Votes WithheldMr. Ross Beaty – Chair 496,065,998...

BEIJING, May 07, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a Phase II clinical trial of its novel TYK2 inhibitor ICP-488 for the treatment of Sjögren’s syndrome. ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the TYK2 JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases. As Sjögren’s syndrome is associated with the aberrant activation of TYK2...

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. In addition to the shares sold in the initial public offering described above, Odyssey announced a concurrent sale of 1,388,889 shares of common stock...

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, issued the following statement: We encourage shareholders to see Diana’s latest disclosure for what it is: more unsubstantiated falsehoods and misleading statements, designed to distract from the simple truth – Diana is trying to take control of your company at a discount to Genco’s asset value, without paying a control premium and below the current trading price. The Genco Board of Directors is committed to the highest standards of corporate governance and will continue to act in the best interests of our shareholders. You can protect your Genco investment by ignoring Diana and voting “FOR” Genco’s highly qualified...

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the three months ended March 31st, 2026, before markets open on Wednesday, May 13th, 2026. MediPharm Labs executive management team will also host a conference call and webcast on Wednesday, May 13th, 2026, at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. Conference Call Dial in Details:North America Toll-Free: (888) 330-2454International Toll: +1 (240) 789-2714Conference ID: 4921762Participants are asked to dial in approximately 15 minutes before the start of the call. Webcast:A...

Perth, May 08, 2026 (GLOBE NEWSWIRE) — perseus mining appoints new chief operating officer Perth, Western Australia/May 8, 2026/Perseus Mining Limited (ASX/TSX:PRU) is pleased to advise that Mr. Wade Bickley will be joining Perseus’s executive leadership team in the role of Chief Operating Officer (COO) from June 1, 2026. Mr. Bickley will be based in Perseus’s Dubai office. Mr. Bickley has over 25 years of industry experience, with extensive expertise in gold and base metals operations across Australia, West Africa and Southern Africa. In recent years, he has held senior management and executive roles in the mining industry where he has led complex mining operations, processing production systems, major capital projects and operational turnarounds. Previously, Mr. Bickley held the role of General Manager at Obuasi Mine in Ghana...

CALGARY, Alberta, May 07, 2026 (GLOBE NEWSWIRE) — Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) (TSX: BDGI) announced today that it has successfully priced a private placement offering (the “Offering”) of C$300 million aggregate principal amount of senior unsecured notes due 2031 (the “Notes”) at a price of C$1,000 per C$1,000 principal amount of Notes, with an interest rate of 5.375% per annum. The Offering is being made through a syndicate of underwriters led by CIBC World Markets Inc. and TD Securities Inc., as joint bookrunners. Badger intends to use the net proceeds from the Offering to repay indebtedness under its credit facilities, including its term facility. The Offering is expected to close on or about...